Stock Highlights: Threshold Pharmaceuticals Inc. (NASDAQ:THLD), Lumber Liquidators Holdings, Inc. (NYSE:LL), Cara Therapeutics Inc. (NASDAQ:CARA), ORBCOMM, Inc. (NASDAQ:ORBC), Epizyme, Inc. (NASDAQ:EPZM)

On July 30, Threshold Pharmaceuticals Inc. (NASDAQ:THLD) reported financial results for the second quarter 2015. Revenue for the second quarter ended June 30, 2015 was $3.7 million. The operating loss for the second quarter ended June 30, 2015 was $8.9 million. The net loss for the second quarter ended June 30, 2015 was $8.3 million, which included the operating loss of $8.9 million and non-cash income of $0.6 million related to the changes in fair value of the Company’s outstanding warrants and was classified as other income (expense). As of June 30, 2015, Threshold had $67.0 million in cash, cash equivalents and marketable securities, with no debt outstanding. Threshold Pharmaceuticals Inc. (NASDAQ:THLD) belongs to Healthcare sector. Its weekly performance is -1.17%. On last trading day company shares ended up $4.21. Threshold Pharmaceuticals Inc. (NASDAQ:THLD) distance from 50-day simple moving average (SMA50) is 2.61%.

Attorney Steve W. Berman, managing partner of Hagens Berman Sobol Shapiro LLP, has been named co-lead counsel in the high-profile class action against Lumber Liquidators Holdings, Inc. (NYSE:LL) concerning the flooring company’s sales of formaldehyde-tainted flooring. Lumber Liquidators Holdings, Inc. (NYSE:LL) shares fell -8.67% in last trading session and ended the day at $12.12. LL Gross Margin is 38.50% and its return on assets is 8.80%. Lumber Liquidators Holdings, Inc. (NYSE:LL) quarterly performance is -55.23%.

On 06 August, Cara Therapeutics Inc. (NASDAQ:CARA) announced on August 03, that the Company will host a conference call and live audio webcast on Monday, August 10, 2015, at 4:30 p.m. ET to report second quarter 2015 financial results and provide a corporate update. Cara Therapeutics Inc. (NASDAQ:CARA) shares fell -3.32% and was closed at $22.16. CARA EPS growth in last 5 year was 0.00%. Cara Therapeutics Inc. (NASDAQ:CARA) year to date (YTD) performance is 122.27%.

ORBCOMM, Inc. (NASDAQ:ORBC) announced its financial results, the company reported that for Q2 of 2015, Total Revenues were up 85% year-over-year to $44.9 million. Service Revenues were up 61% over the prior year to $24.0 million. Second quarter 2015 Product Sales of $20.9 million were 122% higher than the prior year. ORBCOMM completed the acquisitions of SkyWave and InSync in the first quarter of 2015 which had a positive impact on year-over-year comparisons. Organic revenue growth for the second quarter of 2015 was 20%. ORBCOMM, Inc. (NASDAQ:ORBC) ended the last trading day at $5.77. Company weekly volatility is calculated as 4.06% and price to cash ratio as 5.03. ORBCOMM, Inc. (NASDAQ:ORBC) showed a weekly performance of -5.72%.

Epizyme, Inc. (NASDAQ:EPZM) announced that Robert Bazemore will succeed Robert Gould, Ph.D. as President and Chief Executive Officer of Epizyme, effective September 10, 2015. Robert Bazemore will also join the Epizyme board of directors. Dr. Gould has served on the Epizyme board of directors since 2008 and as CEO for the past five-and-a-half years. Following the transition, he will continue to serve on the board and will serve as a consultant to the company. Epizyme, Inc. (NASDAQ:EPZM) belongs to Healthcare sector. Its weekly performance is -11.33%. On last trading day company shares ended up $19.80. Epizyme, Inc. (NASDAQ:EPZM) distance from 50-day simple moving average (SMA50) is -9.15%.

Leave a Reply

Your email address will not be published. Required fields are marked *